perinatologyРоссийский вестник перинатологии и педиатрииRossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)1027-40652500-2228Ltd. “The National Academy of Pediatric Science and Innovation”perinatology-71Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWSПатология сердечно-сосудистой системы у детей с хроническими болезнями почек: эпидемиология, факторы риска, патогенезCardiovascular system diseases in children with chronic kidney diseases: Epidemiology, risk factors, pathogenesisАксеноваМ. Е.AksenovaM. E.

в.н.с. отделения наследственных и приобретенных болезней почек

Научно-исследовательский клинический институт педиатрии ГБОУ ВПО «РНИМУ им. Н.И. Пирогова», МоскваРоссияN.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, MoscowRussian Federation2015090320166022228Copyright © Ltd. “The National Academy of Pediatric Science and Innovation”, 20162016Ltd. “The National Academy of Pediatric Science and Innovation”Ltd. “The National Academy of Pediatric Science and Innovation”https://www.ped-perinatology.ru/jour/about/submissions#copyrightNoticehttps://www.ped-perinatology.ru/jour/article/view/71

Кардиоваскулярные болезни – частое осложнение хронических заболеваний почек и лидирующая причина смертности больных с терминальной почечной недостаточностью. Поражение сердечно-сосудистой системы при хронических болезнях почек обусловлено ранним формированием традиционных факторов (артериальная гипертензия, дислипидемия) и наличием нефрогенных факторов кардиоваскулярного риска (анемия, диспротеинемия, нарушение фосфорно-кальциевого обмена). Нефрогенные факторы риска определяются характером патологии почек и степенью нарушения почечных функций. Кардиоваскулярные изменения включают ремоделирование сосудистой стенки и миокарда, приводя со временем к нарушению их функции. В статье рассмотрены современные представления о патогенезе развития сердечно-сосудистой патологии у больных с хроническими болезнями почек. 

Cardiovascular disease is a common complication of chronic kidney diseases and a leading cause of death in patients with end-stage renal failure. Involvement of the cardiovascular system in chronic kidney disease is due to the early formation of traditional factors (hypertension, dyslipidemia) and the presence of kidney disease-related cardiovascular risk factors (anemia, dysproteinemia, and calcium and phosphorus metabolic disturbances). The kidney disease-related risk factors are determined by the nature of kidney disease and the degree of renal dysfunction. The cardiovascular changes include remodeling of the vascular wall and myocardium, leading to their dysfunctions with time. The article considers the current views on the pathogenesis of cardiovascular diseases in patients with chronic kidney disease. 

детихроническая болезнь почекартериальная гипертензияатеросклерозгипертрофия миокарда левого желудочкаchildrenchronic kidney diseasehypertensionatherosclerosisleft ventricular hypertrophyReferencesSchiffrin E., Lipman M., Mann J. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 1: 85—97.Schiffrin E., Lipman M., Mann J. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 1: 85—97.US Renal Data System: USRDS 2011 Annual Data Report. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Disgestive and Kidney Diseases, 2011; 163—174.US Renal Data System: USRDS 2011 Annual Data Report. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Disgestive and Kidney Diseases, 2011; 163—174.Mitsnefes M. Cardiovascular morbidity and mortality in children with chronic kidney disease in North America: lessons from the USRDS and NAPRTCS databases. Perit Dial Int 2005; 25: Suppl 3: 120—122.Mitsnefes M. Cardiovascular morbidity and mortality in children with chronic kidney disease in North America: lessons from the USRDS and NAPRTCS databases. Perit Dial Int 2005; 25: Suppl 3: 120—122.Mathews T., Minino A., Osterman M. et al. Annual summary of vital statistics: 2008. Pediatrics 2011; 127: 146—157.Mathews T., Minino A., Osterman M. et al. Annual summary of vital statistics: 2008. Pediatrics 2011; 127: 146—157.2013 USRDS Annual Data Report. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. 2014; 63: Suppl: e295—e306.2013 USRDS Annual Data Report. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. 2014; 63: Suppl: e295—e306.Annual report of European Registry for Children on Renal Replacement Therapy, An update on the registry – October 2014. http://www.espn-reg.orgAnnual report of European Registry for Children on Renal Replacement Therapy, An update on the registry – October 2014. http://www.espn-reg.orgFlynn J., Mitsnefes M., Pierce C. et al. Chronic Kidney Disease in Children Study Group. Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study. Hypertension 2008; 52: 4: 631—725.Flynn J., Mitsnefes M., Pierce C. et al. Chronic Kidney Disease in Children Study Group. Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study. Hypertension 2008; 52: 4: 631—725.Wβhl E., Trivelli A., Picca S. et al. ESCAPE Trial Group. Strict blood-pressure control and progression of renal failure in children. N Engl J Med 2009; 22: 17: 1639—1650.Wβhl E., Trivelli A., Picca S. et al. ESCAPE Trial Group. Strict blood-pressure control and progression of renal failure in children. N Engl J Med 2009; 22: 17: 1639—1650.Wilson A., Schneider M., Cox C. et al. Prevalence and correlates of multiple cardiovascular risk factors in children with chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 12: 2759—2765.Wilson A., Schneider M., Cox C. et al. Prevalence and correlates of multiple cardiovascular risk factors in children with chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 12: 2759—2765.Saland J., Glinsberg H., Fisher E. Dyslipidemia in pediatric renal disease: epidemiology, pathophysiology and management. Curr Opin Pediat 2003; 14: 197—204.Saland J., Glinsberg H., Fisher E. Dyslipidemia in pediatric renal disease: epidemiology, pathophysiology and management. Curr Opin Pediat 2003; 14: 197—204.Saland J. Dyslipidemia in children with chronic kidney disease. Kidney Int 2010; 78: 1154—1163.Saland J. Dyslipidemia in children with chronic kidney disease. Kidney Int 2010; 78: 1154—1163.Fadrowski J. Hemoglobin decline in children with chronic kidney disease: baseline results from the Chronic Kidney Disease in Children Prospective Cohort Study. Clin J Am Soc Nephrol 2008; 3: 457—462.Fadrowski J. Hemoglobin decline in children with chronic kidney disease: baseline results from the Chronic Kidney Disease in Children Prospective Cohort Study. Clin J Am Soc Nephrol 2008; 3: 457—462.Staples A. Anemia and risk of hospitalization in pediatric chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 48—56.Staples A. Anemia and risk of hospitalization in pediatric chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 48—56.Menos S., Valentini R., Hidalgo G. et al. Vitamin D insufficiency and hyperparathyoroidism in children with chronic kidney disease. Pediat Nephrol 2008; 23: 1831—1836.Menos S., Valentini R., Hidalgo G. et al. Vitamin D insufficiency and hyperparathyoroidism in children with chronic kidney disease. Pediat Nephrol 2008; 23: 1831—1836.Rostand S., Drüeke T. Parathyroid hormone, vitamin D and cardiovascular disease in chronic renal failure. Kidney Int 1999; 56: 383—392.Rostand S., Drüeke T. Parathyroid hormone, vitamin D and cardiovascular disease in chronic renal failure. Kidney Int 1999; 56: 383—392.Furth S., Abraham A., Jerry-Fluker J. et al. Metabolic abnormalities, cardiovascular disease risk factors, and GFR decline in children with chronic kidney disease. Clin J Am Soc Nephrol 2011; 9: 2132—2140.Furth S., Abraham A., Jerry-Fluker J. et al. Metabolic abnormalities, cardiovascular disease risk factors, and GFR decline in children with chronic kidney disease. Clin J Am Soc Nephrol 2011; 9: 2132—2140.Iglesias P., Dнez J. Adipose tissue in renal disease: clinical significance and prognostic implications. Nephrol Dial Transplant 2010; 7: 2066—2077.Iglesias P., Dнez J. Adipose tissue in renal disease: clinical significance and prognostic implications. Nephrol Dial Transplant 2010; 7: 2066—2077.O’Seaghdha C., Hwang S., Vasan R. et al. Correlation of renin angiotensin and aldosterone system activity with subcutaneous and visceral adiposity: the framingham heart study. BMC Endocrine Disorders 2012; 12: 13—19.O’Seaghdha C., Hwang S., Vasan R. et al. Correlation of renin angiotensin and aldosterone system activity with subcutaneous and visceral adiposity: the framingham heart study. BMC Endocrine Disorders 2012; 12: 13—19.Flynn C., Bakris G. Interaction between adiponectin and aldosterone. Cardiorenal Med 2011; 2: 96—101.Flynn C., Bakris G. Interaction between adiponectin and aldosterone. Cardiorenal Med 2011; 2: 96—101.Matteuci M., Wühl E., Pica S. et al. ESCAPE Trial Group: Left ventricular geometry in children with mild to moderate chronic renal insufficiency. J Am Soc Nephrol 2006; 17: 218—226.Matteuci M., Wühl E., Pica S. et al. ESCAPE Trial Group: Left ventricular geometry in children with mild to moderate chronic renal insufficiency. J Am Soc Nephrol 2006; 17: 218—226.Mitsnefes M. Cardiovascular complications of pediatric chronic kidney disease. Pediat Nephrol 2008; 1: 27—39.Mitsnefes M. Cardiovascular complications of pediatric chronic kidney disease. Pediat Nephrol 2008; 1: 27—39.Mitsnefes M., Kimball T., Kartal J. et al. Progression of left ventricular hypertrophy in children with early chronic kidney disease: 2-year follow-up study. J Pediat 2006; 5: 671—675.Mitsnefes M., Kimball T., Kartal J. et al. Progression of left ventricular hypertrophy in children with early chronic kidney disease: 2-year follow-up study. J Pediat 2006; 5: 671—675.Shroff R., Weaver D., Mitsnefes M. Cardiovascular complications in children with chronic kidney disease. Nat Rev Nephrol 2011; 11: 642—649.Shroff R., Weaver D., Mitsnefes M. Cardiovascular complications in children with chronic kidney disease. Nat Rev Nephrol 2011; 11: 642—649.Chavers B., Solid C., Sinaiko A. et al. Diagnosis of cardiac disease in pediatric end-stage renal disease. Nephrol Dial Transplant 2011; 5: 1640—1645.Chavers B., Solid C., Sinaiko A. et al. Diagnosis of cardiac disease in pediatric end-stage renal disease. Nephrol Dial Transplant 2011; 5: 1640—1645.Litwin M., Wühl E., Jordan C. et al. Evolution of large-vessel arteriopathy in paediatric patients with chronic kidney disease. Nephrol Dial Transplant 2008; 23: 2552—2557.Litwin M., Wühl E., Jordan C. et al. Evolution of large-vessel arteriopathy in paediatric patients with chronic kidney disease. Nephrol Dial Transplant 2008; 23: 2552—2557.Shroff R., Donald A., Hiorns M. et al. Mineral metabolism and vascular damage in children on dialysis. J Am Soc Nephrol 2007; 18: 2996—3003.Shroff R., Donald A., Hiorns M. et al. Mineral metabolism and vascular damage in children on dialysis. J Am Soc Nephrol 2007; 18: 2996—3003.Musheites J., Meyer A., Drueckler E. et al. Assessment of the cardiovascular system in pediatric chronic kidney disease: A pilot study. Pediat Transplant 2008; 12: 412—419.Musheites J., Meyer A., Drueckler E. et al. Assessment of the cardiovascular system in pediatric chronic kidney disease: A pilot study. Pediat Transplant 2008; 12: 412—419.Ziolkowska H., Brzewski M., Roszkowska-Blaim M. Determination of the intima-media thickness in children and adolescents with chronic kidney disease. Pediat Nephrol 2008; 23: 805—811.Ziolkowska H., Brzewski M., Roszkowska-Blaim M. Determination of the intima-media thickness in children and adolescents with chronic kidney disease. Pediat Nephrol 2008; 23: 805—811.Civilibal M., Caliskan S., Kurugoglu S. et al. Progression of coronary calcification in pediatric chronic kidney disease stage 5. Pediat Nephrol 2009; 24: 555—563.Civilibal M., Caliskan S., Kurugoglu S. et al. Progression of coronary calcification in pediatric chronic kidney disease stage 5. Pediat Nephrol 2009; 24: 555—563.Lee J., O’Keefe J., Bell D. et al. Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol 2008; 52: 1949—1956.Lee J., O’Keefe J., Bell D. et al. Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol 2008; 52: 1949—1956.Drueke T., Massy Z. Role of vitamin D in vascular calcification: bad guy or good guy? Nephrol Dial Transplant 2012; 27: 1704—1707.Drueke T., Massy Z. Role of vitamin D in vascular calcification: bad guy or good guy? Nephrol Dial Transplant 2012; 27: 1704—1707.Shroff R. A bimodal association of vitamin D levels and vascular disease in children on dialysis. J Am Soc Nephrol 2008; 19: 1239—1269.Shroff R. A bimodal association of vitamin D levels and vascular disease in children on dialysis. J Am Soc Nephrol 2008; 19: 1239—1269.Zittermann A., Schleitgoff S., Koerfer R. Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr 2005; 94: 483—492.Zittermann A., Schleitgoff S., Koerfer R. Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr 2005; 94: 483—492.Johnstone L. Left ventricular abnormalities in children, adolescents and young adults with renal disease. Kidney Int 1996; 50: 998—1006.Johnstone L. Left ventricular abnormalities in children, adolescents and young adults with renal disease. Kidney Int 1996; 50: 998—1006.Chen S., Chang J., Liu W. et al. Echocardiographic parameters are independently associated with increased cardiovascular events in patients with chronic kidney disease. Nephrol Dial Transplant 2012; 27: 1064—1070.Chen S., Chang J., Liu W. et al. Echocardiographic parameters are independently associated with increased cardiovascular events in patients with chronic kidney disease. Nephrol Dial Transplant 2012; 27: 1064—1070.Krishnasamy R., Isbel N., Hawley C. et al. The association between left ventricular global longitudinal strain, renal impairment and all-cause mortality. Nephrol Dial Transplant 2014; 29: 1218—1225.Krishnasamy R., Isbel N., Hawley C. et al. The association between left ventricular global longitudinal strain, renal impairment and all-cause mortality. Nephrol Dial Transplant 2014; 29: 1218—1225.Lande M., Flynn J. Treatment of hypertension in children and adolescents. Pediat Nephrol 2009; 24: 1939—1949.Lande M., Flynn J. Treatment of hypertension in children and adolescents. Pediat Nephrol 2009; 24: 1939—1949.Falkner B.. Hypertension in children and adolescents: epidemiology and natural history. Pediat Nephrol 2010; 25: 1219— 1224.Falkner B.. Hypertension in children and adolescents: epidemiology and natural history. Pediat Nephrol 2010; 25: 1219— 1224.Kupferman J., Friedman A., Cox C. et al. CKiD Study Group. BP control and left ventricular hypertrophy regression in children with CKD. J Am Soc Nephrol 2014; 25: 167—174.Kupferman J., Friedman A., Cox C. et al. CKiD Study Group. BP control and left ventricular hypertrophy regression in children with CKD. J Am Soc Nephrol 2014; 25: 167—174.Tonelli M., Wiebe N., Culleton B. et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17: 2034—2047.Tonelli M., Wiebe N., Culleton B. et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17: 2034—2047.Sinha M., Tibby S., Rasmussen P.D. et al. Blood Pressure Control and Left Ventricular Mass in Children with Chronic Kidney Disease. Clin J Am Soc Nephrol 2011; 6: 543—551.Sinha M., Tibby S., Rasmussen P.D. et al. Blood Pressure Control and Left Ventricular Mass in Children with Chronic Kidney Disease. Clin J Am Soc Nephrol 2011; 6: 543—551.Wilson A., Mitsnefes M. Cardiovascular disease in CKD in children: update on risk factors, risk assessment, and management. Am J Kidney Dis 2009; 54: 345—360.Wilson A., Mitsnefes M. Cardiovascular disease in CKD in children: update on risk factors, risk assessment, and management. Am J Kidney Dis 2009; 54: 345—360.Mitsnefes M., Ho P., McEnery P. Hypertension and progression of chronic renal insufficiency in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). J Am Soc Nephrol 2003; 14: 2618—2622.Mitsnefes M., Ho P., McEnery P. Hypertension and progression of chronic renal insufficiency in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). J Am Soc Nephrol 2003; 14: 2618—2622.Agarwal R. Ambulatory blood pressure and cardiovascular events in chronic kidney disease. Semin Nephrol 2007; 27: 538—543.Agarwal R. Ambulatory blood pressure and cardiovascular events in chronic kidney disease. Semin Nephrol 2007; 27: 538—543.Mitsnefes M., Flynn J., Cohn S. et al. CKiD Study Group. Masked hypertension associates with left ventricular hypertrophy in children with CKD. Am Soc Nephrol 2010; 21: 137—144.Mitsnefes M., Flynn J., Cohn S. et al. CKiD Study Group. Masked hypertension associates with left ventricular hypertrophy in children with CKD. Am Soc Nephrol 2010; 21: 137—144.Vanholder R., Massy Z., Argiles A. et al. European Uremic Toxin Work Group. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048—1056.Vanholder R., Massy Z., Argiles A. et al. European Uremic Toxin Work Group. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048—1056.Copelovitch L., Warady B., Furth S. Insights from the Chronic Kidney Disease in Children (CKiD) study. Clin J Am Soc Nephrol 2011; 6: 2047—2053.Copelovitch L., Warady B., Furth S. Insights from the Chronic Kidney Disease in Children (CKiD) study. Clin J Am Soc Nephrol 2011; 6: 2047—2053.Mallamaci F., Tripepi G., Maas R. et al .Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J Am Soc Nephrol 2004; 15: 435—441.Mallamaci F., Tripepi G., Maas R. et al .Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J Am Soc Nephrol 2004; 15: 435—441.Barletta G., Flynn J., Mitsnefes M. et al. Heart rate and blood pressure variability in children with chronic kidney disease: a report from the CKiD study. Pediat Nephrol 2014; 29: 1059—1065.Barletta G., Flynn J., Mitsnefes M. et al. Heart rate and blood pressure variability in children with chronic kidney disease: a report from the CKiD study. Pediat Nephrol 2014; 29: 1059—1065.Desir G., Peixoto A. Renalase in hypertension and kidney disease. Nephrol Dial Transplant 2014; 29: 22—28.Desir G., Peixoto A. Renalase in hypertension and kidney disease. Nephrol Dial Transplant 2014; 29: 22—28.Urbina E., Williams R., Alpert B. et al. American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young. Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart Association. Hypertension 2009; 54: 919—950.Urbina E., Williams R., Alpert B. et al. American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young. Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart Association. Hypertension 2009; 54: 919—950.Zoccali C., Bode-Bцger S., Mallamaci F. et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113—2117.Zoccali C., Bode-Bцger S., Mallamaci F. et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113—2117.Matsuguma K., Ueda S., Yamagishi S. et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol 2006; 17: 2176—2183.Matsuguma K., Ueda S., Yamagishi S. et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol 2006; 17: 2176—2183.Garcia-Bello J., Gómez-Díaz R., Contreras-Rodríguez A. et al. Carotid intima media thickness, oxidative stress, and inflammation in children with chronic kidney disease. Pediat Nephrol 2014; 29: 273—281.Garcia-Bello J., Gómez-Díaz R., Contreras-Rodríguez A. et al. Carotid intima media thickness, oxidative stress, and inflammation in children with chronic kidney disease. Pediat Nephrol 2014; 29: 273—281.Jonson R., Leopold J., Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implication. Circ Res 2006; 99: 1044—1059.Jonson R., Leopold J., Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implication. Circ Res 2006; 99: 1044—1059.Moe S., Reslerova M., Ketteler M. et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005; 67: 2295—2304.Moe S., Reslerova M., Ketteler M. et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005; 67: 2295—2304.Takeda S., Elefteriou F., Levasseur R. et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002;111:305—317.Takeda S., Elefteriou F., Levasseur R. et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002;111:305—317.Matteucci M., Chinali M., Rinelli G. et al. ESCAPE Trial Group. Change in cardiac geometry and function in CKD children during strict BP control: a randomized study. Clin J Am Soc Nephrol 2013; 8: 203—210.Matteucci M., Chinali M., Rinelli G. et al. ESCAPE Trial Group. Change in cardiac geometry and function in CKD children during strict BP control: a randomized study. Clin J Am Soc Nephrol 2013; 8: 203—210.Alhaj E., Alhaj N., Rahman I. et al. Uremic cardiomyopathy: an underdiagnosed disease. Congest Heart Fail 2013; 19: E40—45.Alhaj E., Alhaj N., Rahman I. et al. Uremic cardiomyopathy: an underdiagnosed disease. Congest Heart Fail 2013; 19: E40—45.Despa S., Lingrel J. Na+/K+-ATPase б2-isoform preferentially modulates Ca2+ transients and sarcoplasmic reticulum Ca2+ release in cardiac myocytes. Cardiovasc Res 2012; 95: 480—486.Despa S., Lingrel J. Na+/K+-ATPase б2-isoform preferentially modulates Ca2+ transients and sarcoplasmic reticulum Ca2+ release in cardiac myocytes. Cardiovasc Res 2012; 95: 480—486.Kennedy D., Malhotra D., Shapiro J. Molecular insights into uremic cardiomyopathy: cardiotonic steroids and Na/K ATPase signaling. Cell Mol Biol 2006; 52: 3—14.Kennedy D., Malhotra D., Shapiro J. Molecular insights into uremic cardiomyopathy: cardiotonic steroids and Na/K ATPase signaling. Cell Mol Biol 2006; 52: 3—14.Shinohara K., Shoji T., Emoto M. et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 1894—1900.Shinohara K., Shoji T., Emoto M. et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 1894—1900.Semple D., Smith K., Bhandari S. et al. Uremic cardiomyopathy and insulin resistance: a critical role for akt? J Am Soc Nephrol 2011; 22: 207—215.Semple D., Smith K., Bhandari S. et al. Uremic cardiomyopathy and insulin resistance: a critical role for akt? J Am Soc Nephrol 2011; 22: 207—215.Briet M., Schiffrin E.L. Aldosterone: effects on the kidney and cardiovascular system. Nature Reviews Nephrology 2010; 6: 261—273.Briet M., Schiffrin E.L. Aldosterone: effects on the kidney and cardiovascular system. Nature Reviews Nephrology 2010; 6: 261—273.Pacurari M., Kafoury R., Tchounwou P.B. et al. The Renin-Angiotensin- Aldosterone System in Vascular Inflammation and Remodeling. International Journal of Inflammation 2014; 6: 212—220.Pacurari M., Kafoury R., Tchounwou P.B. et al. The Renin-Angiotensin- Aldosterone System in Vascular Inflammation and Remodeling. International Journal of Inflammation 2014; 6: 212—220.Edwards N., Steeds R., Stewart P. et al. Effect of spironolactone on left ventricular mass and aortic stiffness in earlystage chronic kidney disease: a randomized controlled trial. Am Coll Cardiol 2009; 54: 505—512.Edwards N., Steeds R., Stewart P. et al. Effect of spironolactone on left ventricular mass and aortic stiffness in earlystage chronic kidney disease: a randomized controlled trial. Am Coll Cardiol 2009; 54: 505—512.Fischer S., Kempe D., Leibrock C. et al. Hyperaldosteronism in Klotho-deficient mice. Am J Physiol Renal Physiol 2010; 299: F1171—1177.Fischer S., Kempe D., Leibrock C. et al. Hyperaldosteronism in Klotho-deficient mice. Am J Physiol Renal Physiol 2010; 299: F1171—1177.Andersson P., Rydberg E., Willenheimer R. Primary hyperparathyroidism and heart disease. Eur Heart J 2004; 25: 1776— 1787.Andersson P., Rydberg E., Willenheimer R. Primary hyperparathyroidism and heart disease. Eur Heart J 2004; 25: 1776— 1787.Seeherunvong W., Abitbol C., Chandar J. et al. Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis. Pediat Nephrol 2012; 27: 2129—2136.Seeherunvong W., Abitbol C., Chandar J. et al. Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis. Pediat Nephrol 2012; 27: 2129—2136.Agarwal I., Ide N., Ix J. et al. Fibroblast growth factor-23 and cardiac structure and function. J Am Heart Assoc 2014; 13: e000584.Agarwal I., Ide N., Ix J. et al. Fibroblast growth factor-23 and cardiac structure and function. J Am Heart Assoc 2014; 13: e000584.Isakova T., Houston J., Santacruz L. et al. Associations between fibroblast growth factor 23 and cardiac characteristics in pediatric heart failure. Pediat Nephrol 2013; 28: 2035—2042.Isakova T., Houston J., Santacruz L. et al. Associations between fibroblast growth factor 23 and cardiac characteristics in pediatric heart failure. Pediat Nephrol 2013; 28: 2035—2042.Juppner H., Wolf M., Salusky I. FGF-23: more than a regulator of renal phosphate handling? J Bone Miner Res 2010; 25: 2091—2097.Juppner H., Wolf M., Salusky I. FGF-23: more than a regulator of renal phosphate handling? J Bone Miner Res 2010; 25: 2091—2097.Mitsnefes M., Kimball T., Border W. et al. Impaired left ventricular diastolic function in children with chronic renal failure. Kidney Int 2004; 65: 1461—1466.Mitsnefes M., Kimball T., Border W. et al. Impaired left ventricular diastolic function in children with chronic renal failure. Kidney Int 2004; 65: 1461—1466.Shamszad P., Slesnick T., Smith E. et al. Association between left ventricular mass index and cardiac function in pediatric dialysis patients. Pediat Nephrol 2012; 27: 835—841.Shamszad P., Slesnick T., Smith E. et al. Association between left ventricular mass index and cardiac function in pediatric dialysis patients. Pediat Nephrol 2012; 27: 835—841.Mencarelli F., Fabi M., Corazzi V. et al. Left ventricular mass and cardiac function in a population of children with chronic kidney disease. Pediat Nephrol 2014; 29: 893—900.Mencarelli F., Fabi M., Corazzi V. et al. Left ventricular mass and cardiac function in a population of children with chronic kidney disease. Pediat Nephrol 2014; 29: 893—900.

The authors declare that there are no conflicts of interest present.